Data from Multiple Clinical Trials of OrbusNeich’s Genous(TM) Stent Set for Presentation at EuroPCR 2011
HONG KONG, May 12, 2011 /PRNewswire/ — OrbusNeich today announced that data from multiple studies of the Genous Stent will be presented at EuroPCR 2011 in Paris. Clinical studies supporting the use of the Genous Stent and its endothelial progenitor cell (EPC) capture technology in cases where prolonged dual antiplatelet therapy is not advisable will be presented during the HEALING Symposium and in the scientific sessions.
The HEALING Symposium, also titled “How to assess and treat patients who are not suitable candidates for prolonged dual antiplatelet therapy,” will take place at noon CET on Thursday, May 19, in Room Maillot. Michael Haude, M.D., of Medical Clinic I at the Lukaskrankenhaus in Neuss, Germany, and Sigmund Silber, M.D., Ph.D., of Kardiologische Klinik Dr Muller, Munich, will chair the event. The symposium will focus on situations where patients are contraindicated for dual antiplatelet therapy, and consequently drug eluting stents, and the potential for pro-healing stent technology to address these challenging cases.
- Eric Duckers, M.D., Ph.D., of Erasmus University Medical Center in The Netherlands will present data about the mechanism of action and potential benefits of EPC capture technology in an ex vivo arteriovenous (AV) shunt model of human circulating blood.
- Jonathan Hill, M.D., of King’s College in London will provide an overview of those cases in which patients are not ideal candidates for prolonged dual antiplatelet therapy and for which there are potential treatment alternatives.
- Stephen Wai-Luen Lee, M.D., of Queen Mary Hospital in Hong Kong will speak about imaging tools and techniques that can be used to assess arterial healing in patients following percutaneous coronary intervention.
- Robbert de Winter, M.D., Ph.D., of the Academic Medical Center, Amsterdam, will discuss potential requirements for an optimal stent platform in the future.
Dr. Duckers will also present data along with Renu Virmani, M.D., of the CVPath Institute Inc., in Gaithersburg, Md., during the scientific sessions. They will each present clinical data demonstrating that the Genous stent accelerates re-endothelialization and reduces thrombogenicity compared to bare metal stents (BMS) through the capture of circulating EPCs. The presentations are part of an innovation session titled “New stents: pre-clinical studies” taking place at 3 p.m. CET on Wednesday, May 18, in Room 253.
R. Ahmed, M.D., of the EMO Centro Cuore Columbus and San Raffaele Hospital, Milan, Italy, will present data evaluating the safety of very short-term dual antiplatelet therapy after Genous stent implantation as part of a clinical session titled “Is stent thrombosis still an issue?” taking place at 11 a.m. CET on Friday, May 20, in Room 253.
Genous is OrbusNeich’s patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. Development stage products include the Combo(TM) Bio-engineered Sirolimus Eluting Stent, or Combo Stent, which combines the Genous pro-healing technology for rapid endothelial coverage with an abluminal sirolimus drug elution for the control of neointimal proliferation. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com. Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich.
Editor’s Note: OrbusNeich’s Genous stent will be on display at booth No. N06 at EuroPCR 2011.